¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º bN=P*hdf  
VS|2|n1<6  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ TJ*T:?>e  
]K%!@O!  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) 'we>q@  
/wlEe>i  
1. ICAM-1 LXCx~;{\  
{Hk}Kow  
2. interleukin 12(IL-12) W!(LF7_!  
t ZB<on<.)  
3. tumor infiltrating lymphocyte h FBe,'3M  
Vf1^4 t  
4. TCR/CD3 complex N4HqLh 23H  
Z$? #  
5. hematopoietin receptor family 2b8L\$1q  
(C)p9-,  
6. individual idiotype(IdI) f|oh.z_R  
Ssg&QI  
7. integrin 9-m=*|p  
caX< n>  
8. colony-stimulatory factor (CSF) Z<{QaY$"  
5Jnlz@P9  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© I1&aM}y{G  
{BU;$  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? (&x['IR  
g< .qUBPKX  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£  "-V"=t'  
h2J x]FJ  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ^T-V ^^#(  
KJZ4AWH`  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ A\5L 7  
@pU)_d!pJ  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) _v]MsT-q  
0#^v{DC  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ Aq7osU1B  
0_t!T'jr7  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) S ByW[JE  
H} g{Cr"Ex  
3. immunoglobulin superfamily (IgSF) ;sFF+^~L  
4H]L~^CD  
4. selectin jrh43 \$*  
$* Kvc$D  
5. anti-idiotypic antibody (¦ÁId) wq`Bd  
:*\Pn!r  
6. major histocompatibility complex(MHC) 3? +Hd  
'2^Q1{ :\  
7. immunotolerance :9 ^* ^T  
Q]>.b%s[  
8. biological reponse modifier(BRM) pyvSwD5t  
?6Y?a2 |  
9. immune reponse gene (Ir gene) a:6m7U)P#5  
wD)XjX  
10. reshaped antibody (or reconstituted antibody) MFk5K  
o " #\ >  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© ~/P[J  
wAW5 Z0D  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ %bfQ$a:  
S^\Vgi(  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? W6/ yn  
:20W\P<O!A  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ 3/n5#&c\4  
JFk lUgg  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? u4 h4.NHX  
~IN>3\j  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ JcxThZP~  
y_lU=(%Jd  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? E=!\z%4  
j  e P  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ %OOl'o"V{s  
j#q-^h3H  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ ;hN!s`vq  
G*P#]eO  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? 7E~;xn;  
Z}Ft:7   
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ ^,T(mKS  
:!!at:>  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: b B3powy9  
:^B1~p(?sK  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ZX./P 0  
]|P iF+  
ÃâÒßѧ n]o<S+z  
x-&@wMqkc  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© lp%pbx43s  
H ]Z$OpI  
1. CD8 x)O!["'"  
> jc [nk  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) 0{}8(  
K/yxE|w<  
3. immunoglobulin fold(Ig fold) ]Ntmy;Q   
=R$u[~Xl2X  
4. cadherin (Ca-dependent cell adhesion moleculers) VY=jc~c]v  
dn$!&  
5. idiotype-anti-idiotypic antibody immune network theory PmEsN&YP]  
0rs"o-s<  
6. HLA class II antigen 8\A#CQ5b  
!9VY|&fHe  
7. complementarity-determining region (CDR) 1JG'%8}#8  
~YWQ2]  
8. perforin(or pore-forming protein ,PFP) y'nK>)WG4  
u[=r,^YQ  
9. high affinity IL-2 receptor ShP^A"Do  
Zaf:fsj>  
10. artificial active immunization a P@N)"  
2E)-M9ds  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© fW1CFRHH  
U}rU~3N  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ,~@X{7U  
SBk4_J/_  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 6@F9G 4<Z  
dhf!o0'1M  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ BLf>_b Uk  
g63(E,;;J  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ _P 3G  
SaAFz&WRl  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ s %``H`  
0#s"e}@v  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? /1V xc 6  
o!Ieb  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ l<LP&  
r|fL&dtr  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ _~J {wM  
^?7-r6  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ Kp~VS<3  
rv^@,8vq  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ P%:wAYz1^O  
HU8900k+  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© p{ Yv3dNl  
Vvn2 Ep  
1. immunoglobulin gene rearrangement ll<Xz((o  
t?x<g<PJ4  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) r6MMCJ|G  
7u S~MW  
3. flow cytometry(FCM) 7Oa#c<2]  
QQ*hCyw!  
4. carrier effect 6xe*E[#k\  
QT< }] 0  
5. positive selection of T lymphocytes in thymus Q_Q''j(r6b  
6 Z6'}BDP  
6. mouse TH1(Th1) and TH2(Th2) subsets @fZ,.2ar  
( iBl   
7. perforin (pore-forming protein ,PFP) av}k)ZT_  
U8s2|G;K  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) fIx+IL s  
a+[KI  
9. SH-2(src-homology region 2) <.x{|p  
aD<A.Lhy  
10. Ab2¦Â (internal image) y2Q&s 9$Do  
mDA:nx%5<  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© #`qx<y*S  
2RVN\?s:  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? WrnrFz  
/QK6Rac-  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? gDQ^)1k  
MD}w Y><C  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠwjU9ZGM  
DzAg"6=CS  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ AVsDt2A  
2jA{SY-  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠn2"a{Ofhlf  
+C^nO=[E  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) w1F cB$  
prUN)r@U   
ÃâÒßѧרҵ£º #>a\>iKQ2q  
vO H4#  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ y B81f  
] 7[ 3>IN  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? /m!BY}4W  
Zcey|m*|  
´«È¾²¡Ñ§×¨Òµ£º .y' >[  
WSP I|#Xr%  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ j}#w )M  
Ky`qskvu  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ w$>u b@=  
]HbY  
Ïû»¯×¨Òµ£º HRpte=`q  
Q*GN`07@?d  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ QDZWX`qw{  
Q@=Q0  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? M.JA.I@XC  
l& [O  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ )|cc X  
xKbXt;l2  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 4a&RYx  
V(}:=eK  
1. Fas(CD95)/FasL pt?bWyKG  
A]*}HZ ,  
2. common chain of cytokine receptor z>xmRs   
}f%}v  
3 . TCR/CD3 complex aNsBcov3O  
5; C|  
4. negaive selection of thymocytes :x3QRF  
_r#Z}HK  
5. artificial active immune H;mSkRD3N  
TT%M' 5&  
6. anti-idiotypic e v}S+!|U  
RIR\']WN  
7. IgSF BX/8O<s0  
`b&%Hm  
8. Integrin i%iL[id:w  
xa'*P=<)C'  
9. chemokine xh-o}8*n"  
/A\8 mL8  
10. B7/CD28 Ng &% o  
+bxYG D  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© >dXGee>'M  
rw[ph[\X  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ (y'hyJo  
sfH_5 #w  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ D>r&}6<  
Rr$-tYy6  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ G&SB-  
~%F9%=  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ .~db4d]  
jwe*(k]z  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ %QH$ipM  
yF:1( 4  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ t,Lrfv])  
G5_=H,Vmd  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© D8Ic?:iX[  
r r %V.r;2  
1. B7/CD28 ^6x %*/l|  
A Q U+mo  
2. Th1 subset KkyVSoD\  
unzr0x {  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© M^Yh|%M  
,,.QfUj/&  
4. antibody affinity maturation YqD=>P[O  
I|!OY`ko  
5. AP-1 c ]-<vkpV  
5I;&mW`1,`  
6. single chain variable fragment£¨ScFv£© N% B>M7-=  
Paq4  
7. NK cell receptor @;4zrzQi7  
nPtuTySG  
8. Zinkernagel-Doherty phenomenon qwcD`HV,  
3*bU6$|5FP  
9. Ig fold By,eETU]  
iyE7V_O T  
10. CD40/CD40L X JB)rP  
59L\|OR  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© cZ*@$%_  
@4C% +-  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ Oszj$C(jF  
"{xrL4BtC  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ D) P._?  
1.hyCTnI  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ G4;Oi=  
Qel9G($=  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ `(;m?<%  
2pCaX\t  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ Ne!lH@ql  
?z+eWL  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ Gz0]}]A  
`}\ "Aw c  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ >'$Mp<  
RB\uK 1+  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© ~ Iuf}D;  
NxY#NaE:?4  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© f~[7t:WD*  
@HCVmg:  
1.Co-stimulators (or co-stimulating molecules) [|L<_.8  
]W!0$'o  
2.NK-kB vr l-$ii  
}.(B}/$u  
3.Immunoglobulin superfamily $%Kf q[Q  
:Yl-w-oe  
4.antigen-presenting cell (APC) 3d]S!=4H"  
x,- 75  
5.death domain t{kG<J/l  
F>l] 9!P|m  
6.CCR and CXCR d0ks G$  
SH$PwJU  
7.Lectin (or mitogen) A/s?x>QA  
=T@1@w  
8.Clusters of differentiation, CD) * u>\57W  
KpGhQdR#  
9.B7 family tWRC$  
4HlQ&2O%#  
10.Cytotoxic T lymphocyte, CTL) D@.6>:;il  
o* H<K aX  
11.IL-15 and IL-15 receptor (IL-15R) cwg"c4V  
D,feF9  
12.MHC restriction wHy!CP %  
&QgR*,5eo  
13.Affinity-chromatography }7Q%6&IR  
y)@wjH{6  
14.Cyctosprin A, CsA o+'6`g'8  
(<9u-HF#  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) [W&T(%(W-  
?@86P|19  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© g 7H(PF?  
M= (u]%\  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 $UwCMPs X  
2^7`mES  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ <hyKu  
a7opCmL  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ CU0YIL  
W>r+h -kR  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© Pq$n5fZC !  
e0 ecD3  
ÃâÒßѧרҵ£º p_4<6{KEt  
:3 mh@[V  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ ]SE ZaT  
u ga_T  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ ;'1d1\wiDQ  
u3 D)M%e  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ h68 xet;  
(9)Q ' 'S  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) 3so %gvY.'  
WIGi51yC.x  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) =_^X3z0  
pj(,Zd[47  
1. ADCC(antibody dependent cell-mediated cytotoxicity) W,u:gzmhw  
zuCSj~  
2. »·æß¾úËØ(cyclosporin) W g! Lfu  
<VE@DBWyl~  
3. KIR(killer cell inhibitory receptor) pR_9NfV{  
Bw yx c  
4. HLDA(human leucocyte differentiation antigen) $cg cX  
6\t@)=C,Q  
5. Interleukin 18(IL-18) wC*X4 '  
lq uLT6]  
6. ÕûºÏËØ(integrin) jiGTA:v  
gM]:Ma  
7. Fas/FasL c@Is2 9t*  
xD7]C|8o  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) kxCSs7J/  
 :11 A  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) 3g B7g'U  
)%]J>&/0J  
10. Th1/Th2 x1<|hTPk  
~M$Wd2Th  
11. »ùÒòÒßÃç(DNAÒßÃç) so s5Y}  
ykJ>*z  
12. chemokines and chemokine receptor u@^LW<eD  
wM{s|Ay  
13. ÃâÒßÄÍÊÜ DfB7*+x{  
VaPG-n>Vf  
14. ¹²´Ì¼¤·Ö×Ó =lSNs   
w(F%^o\  
15. ËÀÍö½á¹¹Óò(death domain) ipz5H*  
}a/Cro.~4  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) 0{mex4  
('~LMu_  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? [hs ds\  
:KO2| v\  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠJS77M-Ac  
?ubro0F:  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î AwN!;t_0+N  
]^]wP]R_  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ u:EiwRW  
M=Wz  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå jdBLsy@  
"#48% -'x  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ Dh*n!7lD`  
@PU [:;  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) 0$njMnB2l  
Js;h%  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ pJ{Y lS{  
D,6:EV"sa  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ 7o4\oRGV  
m kexc~l  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
freekaobo¹Ù·½Î¢ÐŶ©ÔĺŠÕýÈ·´ð°¸:¿¼²©
°´"Ctrl+Enter"Ö±½ÓÌá½»